Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.52 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3721473 | 0.91 | PTGS1 (0.52) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL628352 | 0.90 | GLO1 (0.49) | PTGS1GSTK1GLO1NOD1 | |
| S-Nitrosoglutathione SCHEMBL17619393 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL28090640 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL30637209 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL154575 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL1147641 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL154574 | 0.88 | PTGS1 (0.67) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| SCHEMBL4250989 | 0.87 | PTGS1 (0.47) | PTGS1GSTK1GLO1NOD1FOLH1 | |
| S-Nitrosoglutathione SCHEMBL29261007 | 0.87 | PTGS1 (0.65) | PTGS1GSTK1GLO1NOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772278-B2 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7449595-B2 | for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions | NITROMED, INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070112067-A1 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | NITROMED, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| US-7176238-B1 | Nitrostated and nitrosylated prostaglandins, compositions and methods of use | NITROMED INC. (US) | 2007-02-13 | — | — | US | disclosed |
| WO-2000051978-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METODS OF USE | NITROMED, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999055317-A2 | TREATMENT OF ADVANCED DECOMPENSATED HEART FAILURE WITH NITRIC OXIDE DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088366-A1 | NITROSATED AND NITROSYLATED PROSTAGLANDINS, COMPOSITIONS AND METHODS OF USE | PTGIS, PGF, PTGS1 | PTGS1 3/4885GSTK1 63/4885GLO1 208/4885 |
| US-20070112067-A1 | Nitrosated and nitrosylated prostaglandins, compositions and methods of use | PTGIS, PGF, PTGS1 | PTGS1 3/4885GSTK1 63/4885GLO1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.